ProKidney Corp. (PROK)
NASDAQ: PROK · Real-Time Price · USD
0.7500
+0.0286 (3.96%)
At close: May 12, 2025, 4:00 PM
0.7590
+0.0090 (1.20%)
After-hours: May 12, 2025, 5:55 PM EDT
Company Description
ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States.
Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes.
The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel.
ProKidney Corp. was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
ProKidney Corp.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 204 |
| CEO | Bruce Culleton |
Contact Details
Address: 2000 Frontis Plaza Blvd., Suite 250 Winston-Salem, North Carolina 27103 United States | |
| Phone | 336 999 7028 |
| Website | prokidney.com |
Stock Details
| Ticker Symbol | PROK |
| Exchange | NASDAQ |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001850270 |
| ISIN Number | KYG7S53R1049 |
| Employer ID | 98-1586514 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Bruce Culleton M.D. | Chief Executive Officer and Director |
| Dr. Ulrich Ernst Ph.D. | Executive Vice President of Science and Technology |
| Todd C. Girolamo Esq., J.D., M.B.A. | Chief Legal Officer and Secretary |
| James Coulston CPA | Chief Financial Officer |
| Anu Biswas | Senior Vice President of Manufacturing and Operations |
| Richard Williams | Chief Information Officer |
| Carla Poulson | Chief People Officer |
| Dr. Joseph M. Stavas M.D., M.P.H. | SVice President of Clinical Affairs |
| Dr. Darin J. Weber Ph.D. | Chief Reg. Off, SVice President and Head of Global Reg. Affairs, Quality Mgmt, Biometrics and Market Access |
| Nikhil L. Pereira-Kamath | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 12, 2025 | 8-K | Current Report |
| May 12, 2025 | 10-Q | Quarterly Report |
| May 6, 2025 | SCHEDULE 13G/A | Filing |
| Apr 28, 2025 | EFFECT | Notice of Effectiveness |
| Apr 28, 2025 | ARS | Filing |
| Apr 28, 2025 | 424B3 | Prospectus |
| Mar 31, 2025 | S-4 | Filing |
| Mar 20, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 17, 2025 | 10-K | Annual Report |
| Mar 17, 2025 | 8-K | Current Report |